Viridian Therapeutics, Inc. - ROE
VRDN
Price:
$16.63
Market Cap:
$1.50B
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Industry
Biotechnology
IPO Date
2014-06-18
Stock Exchange
NASDAQ
Ticker
VRDN
PE Ratio
[-4.96]
ROE
[-60.70%]
Current Ratio
[15.15]
Dividend Yield
[0%]
Enterprise Value
[1.37B]
Dividend History
The ROE as of June 2026 (TTM) for Viridian Therapeutics, Inc. (VRDN) is -60.70%
According to Viridian Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -60.70%. This represents a change of 307.42% compared to the average of -14.90% of the last 4 quarters.
Viridian Therapeutics, Inc. (VRDN) Historical ROE (quarterly & annually)
How has VRDN ROE performed in the past?
The mean historical ROE of Viridian Therapeutics, Inc. over the last ten years is 318.06%. The current -60.70% ROE has changed -119.08% with respect to the historical average. Over the past ten years (40 quarters), VRDN's ROE was at its highest in in the December 2016 quarter at 1.71%. The ROE was at its lowest in in the December 2020 quarter at -75.60%.
Average
318.06%
Median
-50.61%
Minimum
-265.79%
Maximum
3.89%
Viridian Therapeutics, Inc. (VRDN) ROE by Quarter and Year
Discovering the peaks and valleys of Viridian Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 317.30%
Maximum Annual ROE = 3.89%
Minimum Annual Increase = -3672.68%
Minimum Annual ROE = -265.79%
| Year | ROE | Change |
|---|---|---|
| 2025 | -47.44% | 18.03% |
| 2024 | -40.19% | -25.27% |
| 2023 | -53.78% | 63.60% |
| 2022 | -32.87% | -22.29% |
| 2021 | -42.30% | -54.13% |
| 2020 | -92.23% | -65.30% |
| 2019 | -265.79% | 317.30% |
| 2018 | -63.69% | -7.48% |
| 2017 | -68.84% | -101.77% |
| 2016 | 3.89% | -3672.68% |
Viridian Therapeutics, Inc. (VRDN) Average ROE
How has VRDN ROE performed in the past?
The current ROE of Viridian Therapeutics, Inc. (VRDN) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-47.14%
5-year avg
-43.32%
10-year avg
318.06%
Viridian Therapeutics, Inc. (VRDN) ROE vs. Peers
How is VRDN’s ROE compared to its peers?
Viridian Therapeutics, Inc.’s ROE is greater than uniQure N.V. (-145.81%), greater than Structure Therapeutics Inc. (-15.14%), greater than Edgewise Therapeutics, Inc. (-32.55%), less than Galapagos N.V. (16.88%), greater than Ocular Therapeutix, Inc. (-64.55%), greater than Vera Therapeutics, Inc. (-74.86%), greater than Arcus Biosciences, Inc. (-68.97%), greater than Celldex Therapeutics, Inc. (-50.72%), less than ImmunityBio, Inc. (138.69%), greater than Cogent Biosciences, Inc. (-83.29%),
| Company | ROE | Market cap |
|---|---|---|
| -145.81% | $2.92B | |
| -15.14% | $2.56B | |
| -32.55% | $3.96B | |
| 16.88% | $1.84B | |
| -64.55% | $2.06B | |
| -74.86% | $2.52B | |
| -68.97% | $2.45B | |
| -50.72% | $2.16B | |
| 138.69% | $7.71B | |
| -83.29% | $5.90B |
Build a custom stock screener for Viridian Therapeutics, Inc. (VRDN) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Viridian Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Viridian Therapeutics, Inc. (VRDN) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Viridian Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Viridian Therapeutics, Inc.'s ROE?
How is the ROE calculated for Viridian Therapeutics, Inc. (VRDN)?
What is the highest ROE for Viridian Therapeutics, Inc. (VRDN)?
What is the 3-year average ROE for Viridian Therapeutics, Inc. (VRDN)?
What is the 5-year average ROE for Viridian Therapeutics, Inc. (VRDN)?
How does the current ROE for Viridian Therapeutics, Inc. (VRDN) compare to its historical average?